Buy & Sell Schwab US Dividend Equity ETF (SCHD) – Schwab US Dividend Equity ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- Broad Market / FactorSector
- -4.61%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 88% Buy | 12% SellTrading Activity
- 24 daysTypical Hold Time
Over the past 52 weeks, Schwab US Dividend Equity ETF has traded between a low of $25.89 and a high of $32.83, highlighting its annual price range. Over the past three months, Schwab US Dividend Equity ETF has recorded a drawdown of -4.61%, reflecting recent price volatility. On average, investors hold Schwab US Dividend Equity ETF for approximately 24 days, indicating typical investor behavior on the platform.
About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Most Recent News
Nasdaq 100 hits record above 30,000 as Micron rallies 18%, driven by AI demand.
The Nasdaq 100 index surpassed 30,000 points during Tuesday's session, led by a strong rally in semiconductor stocks, especially Micron Technology which surged 18%. This rally was fueled by rising expectations for AI-related spending, with UBS raisin...
Uber's $10B robotaxi deal pressures Lucid with heavy manufacturing costs and dilution risks.
Uber's $10 billion commitment to a robotaxi fleet, including a deal for 35,000 autonomous vehicles with Lucid and $750 million equity injections, has raised concerns among investors. Lucid faces significant manufacturing challenges and capital needs ...
Over 75 drugs in development for Duchenne muscular dystrophy signal strong innovation in treatment options.
DelveInsight's 2026 report reveals a robust pipeline with 75+ drugs under development for Duchenne muscular dystrophy (DMD), involving 70+ companies. Key therapies focus on gene and mutation-targeted approaches to slow disease progression, addressing...